Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Basal Cell Carcinoma?

Updated: Mar 23, 2021
  • Author: Robert S Bader, MD; Chief Editor: William D James, MD  more...
  • Print

PD-1/PD-L1 Inhibitors

Cemiplimab (Cemiplimab-rwlc, Libtayo)

Recombinant human immunoglobulin G4 monoclonal antibody binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. It is indicated for locally advanced BCC and granted accelerated approval for metastatic BCC previously treated with a HHI or for whom a HHI is not appropriate.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!